Skip to content
Medical Health Aged Care

Community turns out in force to support people impacted by dementia

Dementia Australia 2 mins read

Thank you to Perth community members who turned up in force to the 2024 Memory Walk & Jog, showing their support for Australians living with dementia.

 

More than 1,000 people walked, ran and jogged on Sunday 26 May raising an impressive total of $140,000!

 

Dementia Australia Executive Director Services, Advocacy & Research Dr Kaele Stokes said it was a wonderful occasion and extended her gratitude to all who participated, raised funds, spread the word and donated.

 

“There was an outstanding show of support from the Perth community who turned out in such large numbers for another year. So many people impacted by dementia find these events a great way to connect with others in similar circumstances. It is such an important day and your support means the world,” Dr Stokes said.

 

Dr Stokes also acknowledged everyone who volunteered at the Perth Memory Walk & Jog.

“It is only through the hard work of our wonderful volunteers that the success of this event is possible.”

The Perth event is one of 22 scheduled Memory Walk & Jogs taking place across Australia in 2024. Details on the remaining events in the series can be found at www.memorywalk.com.au

Dementia Australia is encouraging anyone unable to participate at one of our 22 events to consider organising their own group or individual walk or jog, with a MyWay event. More details can be found at www.memorywalk.com.au/get-involved/mw.

 

Walk or jog with us. We are in this together.

 

 

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.  

 

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au   

-Ends-

Media contacts: Andrea Hogan, Media and Communications Manager, 0406 904 118, andrea.hogan@dementia.org.au

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

Media

More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.